- 125 次围观
产品图片
货号/SKU
NR-54972
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-54972?? pSMART? BAC V2.0 Vector Containing the SARS-Related Coronavirus 2, Wuhan-Hu-1Non-Infectious Replicon(Plasmid/Vectors)|SARS-Related Coronavirus 2|pSMART? BAC V2.0 Vector Containing the SARS-Related Coronavirus 2, Wuhan-Hu-1
Non-Infectious Replicon| -20°C or colder|D WangAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: pSMART? BAC V2.0 Vector Containing the SARS-Related Coronavirus 2, Wuhan-Hu-1 Non-Infectious Replicon, NR-54972.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
Note: Non-infectious replicons produced by use of NR-54972 are a BSL2 organism. Replicon production should be performed with appropriate biosafety controls.
The vector for the non-infectious replicon from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), Wuhan-Hu-1 (GenBank: NC_045512) was designed by cloning a T7 promoter upstream of the SARS-CoV-2 insert and a poly A/HDV ribozyme and T7 terminator cassette downstream and subcloned into the pSMART? BAC V2.0 cloning vector. The spike (S) gene was replaced by a luciferase (Luc2) and enhanced green fluorescent protein (eGFP) fusion construct. The Luc2 gene is a synthetic firefly luciferase gene that has been codon optimized for mammalian expression and has had cryptic transcription factor binding sites removed. The envelope (E) and membrane (M) genes were replaced with a neomycin resistance gene, aminoglycoside transferase. NR-54972 contains the chloramphenicol acetyltransferase gene, cat, to provide transformant selection through chloramphenicol resistance in Escherichia coli (E. coli) and a neomycin selectable marker for mammalian expression. The resulting size of the plasmid is approximately 36000 base pairs. The complete plasmid sequence and map are provided on the BEI Resources webpage. The plasmid was produced in E. coli and extracted.
NR-54972 is used to express a SARS-CoV-2 replicon that is defective in producing progeny virions. The genome is replication competent in multiple cell lines.
Each vial contains plasmid DNA in EB buffer (10 mM Tris-HCl, pH 8.5). The vial should be centrifuged prior to opening. Note: The contents of the vial should be used to replicate the plasmid in E. coli prior to mammalian expression.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
Luc2
Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for money or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene except that researchers may: (1) create fused gene sequences provided that the coding sequence of the resulting luciferase gene has no more than four deoxynucleotides missing at the affected terminus compared to the intact luciferase gene sequence, and (2) insert and remove nucleic acid sequences in splicing research predicated on the inactivation or reconstitution of the luminescence of the encoded luciferase. No other use or transfer of this product or derivatives is authorized without the prior express written consent of Promega. In addition, researchers must either: (1) use luminescent assay reagents purchased from Promega for all determinations of luminescence activity of this product and its derivatives; or (2) contact Promega to obtain a license for use of the product and its derivatives. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA. This label license relates to Promega patents and/or patent applications on improvements to the luciferase gene.
Note: Non-infectious replicons produced by use of NR-54972 are a BSL2 organism. Replicon production should be performed with appropriate biosafety controls.
The vector for the non-infectious replicon from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), Wuhan-Hu-1 (GenBank: NC_045512) was designed by cloning a T7 promoter upstream of the SARS-CoV-2 insert and a poly A/HDV ribozyme and T7 terminator cassette downstream and subcloned into the pSMART? BAC V2.0 cloning vector. The spike (S) gene was replaced by a luciferase (Luc2) and enhanced green fluorescent protein (eGFP) fusion construct. The Luc2 gene is a synthetic firefly luciferase gene that has been codon optimized for mammalian expression and has had cryptic transcription factor binding sites removed. The envelope (E) and membrane (M) genes were replaced with a neomycin resistance gene, aminoglycoside transferase. NR-54972 contains the chloramphenicol acetyltransferase gene, cat, to provide transformant selection through chloramphenicol resistance in Escherichia coli (E. coli) and a neomycin selectable marker for mammalian expression. The resulting size of the plasmid is approximately 36000 base pairs. The complete plasmid sequence and map are provided on the BEI Resources webpage. The plasmid was produced in E. coli and extracted.
NR-54972 is used to express a SARS-CoV-2 replicon that is defective in producing progeny virions. The genome is replication competent in multiple cell lines.
Each vial contains plasmid DNA in EB buffer (10 mM Tris-HCl, pH 8.5). The vial should be centrifuged prior to opening. Note: The contents of the vial should be used to replicate the plasmid in E. coli prior to mammalian expression.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
Luc2
Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for money or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene except that researchers may: (1) create fused gene sequences provided that the coding sequence of the resulting luciferase gene has no more than four deoxynucleotides missing at the affected terminus compared to the intact luciferase gene sequence, and (2) insert and remove nucleic acid sequences in splicing research predicated on the inactivation or reconstitution of the luminescence of the encoded luciferase. No other use or transfer of this product or derivatives is authorized without the prior express written consent of Promega. In addition, researchers must either: (1) use luminescent assay reagents purchased from Promega for all determinations of luminescence activity of this product and its derivatives; or (2) contact Promega to obtain a license for use of the product and its derivatives. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA. This label license relates to Promega patents and/or patent applications on improvements to the luciferase gene.
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.通过此限制的订单将在发货前发送至NIAID进行批准.
注意：通过使用NR-54972产生的非传染性复制子是BSL2生物体.应使用适当的生物安全控制进行复制品生产.
来自严重急性呼吸综合征相关的冠状病毒2（SARS-COV-2）的非传染性复制子的载体，武汉 - HU-1（Genbank： NC_045512 ”，并将T7终止子盒在下游和亚克隆到 psmart ? bac v2.0 克隆载体.峰值由荧光素酶（LUC2）和增强的绿色荧光蛋白（EGFP）融合构建体取代. Luc2基因是一种合成的萤火虫荧光素酶基因，其被针对哺乳动物表达优化的密码子，并且已经除去了隐秘的转录因子结合位点.用新霉素抗性基因，氨基糖苷转移酶代替包膜（E）和膜（M）基因. NR-54972含有氯霉素乙酰转移酶基因，猫，以通过氯霉素（大肠杆菌）抗氯霉素抗性提供转化体选择，以及用于哺乳动物表达的新霉素选择标记.得到的质粒的尺寸约为36000碱基对.在北部资源网页上提供完整的质粒序列和地图.在 e中制备质粒. Coli 并提取.
NR-54972用于表达在生产后代病毒中有缺陷的SARS-COV-2复制品.基因组是多个细胞系中竞争的复制.
每个小瓶含有EB缓冲液中的质粒DNA（10mM Tris-HCl，pH 8.5）.在打开之前应该离心小瓶. 注意：Vial的内容应该用于复制 e中的质粒. Coli 在哺乳动物表达之前.
vipr （病毒病原体资源）提供了附加信息和工具.
Luc2
研究人员可以使用本产品仅供研究，不允许商业用途. “商业用途”是指通过派对或其他代价的缔约方的任何和所有用途，并可能包括但不限于：（1）产品制造; （2）提供服务，信息或数据;和/或转售产品或其衍生物，是否这些产品或衍生物是用于研究的转售.研究人员对荧光素酶基因的核苷酸序列的核苷酸序列的含量没有权利，除了研究人员可以：（1）产生融合基因序列，条件是所得荧光素酶基因的编码序列不超过四个脱氧核苷酸缺失与完整的荧光素酶基因序列相比，受影响的末端，（2）插入并除去剪接研究中的核酸序列，其预先灭活或重构编码的荧光素酶的发光的灭活或重构.未经Promega事先明确书面同意，否则没有其他使用或转移本产品或衍生物.此外，研究人员必须：（1）使用从Promega购买的发光测定试剂用于本产品的发光活动的所有测定及其衍生物;或（2）联系Promega以获得使用产品及其衍生物的许可证.研究人员可以将衍生品传递给其他人进行研究用途，条件规定，在转移此标签许可证的副本时，给予收件人，收件人同意受此标签许可条款的约束.关于此标签许可外的任何用途，包括任何诊断，治疗或预防用途，请联系Promega以供提供和许可信息. Promega没有任何形式的陈述或保证，无论是表达还是暗示，包括用于产品的特定目的的商家或适应性.该标签许可的条款应根据美国威斯康辛州的法律管辖.该标签许可证涉及Promega Patents和/或专利申请改善Luciferase基因.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2024-01-21
2022-06-17
2022-03-31
2022-04-01
2022-04-01
2022-06-17
2022-04-01
2022-04-01
2021-12-02
2021-12-13
2024-06-14
2024-01-21
2022-04-01
2021-12-13
2021-12-21
2019-05-08